HBVtech  has developed a proprietary gene therapy platform designed to address various chronic infections with a single injection.

Our proprietary platform can be applied to address several chronic infections which cannot be addressed by chronically-administered therapies.

​

Our lead program targets chronic hepatitis B (cHBV) infections with a potential for achieving a lasting cure through a single administration. ​​